Log in

NASDAQ:EYEN - Eyenovia Stock Price, Forecast & News

$3.90
+0.13 (+3.45 %)
(As of 02/28/2020 04:00 PM ET)
Today's Range
$3.50
Now: $3.90
$3.90
50-Day Range
$3.66
MA: $4.41
$4.92
52-Week Range
$2.55
Now: $3.90
$6.98
Volume31,200 shs
Average Volume41,895 shs
Market Capitalization$64.12 million
P/E RatioN/A
Dividend YieldN/A
Beta1.45
Eyenovia, Inc, a clinical stage biopharmaceutical company, engages in developing a pipeline of ophthalmology products in the United States. It is developing MicroProst, which is in Phase III clinical trials for the treatment of chronic angle closure glaucoma; MicroStat, which is in Phase III clinical trials for the treatment of mydriasis; MicroTears for the treatment of dry eye; and MicroPine for the treatment of myopia. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EYEN
CUSIPN/A
Phone917-289-1117

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.43 per share

Profitability

Net Income$-17,250,000.00

Miscellaneous

EmployeesN/A
Market Cap$64.12 million
Next Earnings Date3/25/2020 (Estimated)
OptionableNot Optionable

Receive EYEN News and Ratings via Email

Sign-up to receive the latest news and ratings for EYEN and its competitors with MarketBeat's FREE daily newsletter.


Eyenovia (NASDAQ:EYEN) Frequently Asked Questions

What is Eyenovia's stock symbol?

Eyenovia trades on the NASDAQ under the ticker symbol "EYEN."

How were Eyenovia's earnings last quarter?

Eyenovia Inc (NASDAQ:EYEN) issued its earnings results on Wednesday, November, 13th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.34) by $0.05. View Eyenovia's Earnings History.

When is Eyenovia's next earnings date?

Eyenovia is scheduled to release their next quarterly earnings announcement on Wednesday, March 25th 2020. View Earnings Estimates for Eyenovia.

What price target have analysts set for EYEN?

3 Wall Street analysts have issued 12-month price targets for Eyenovia's stock. Their forecasts range from $9.00 to $10.00. On average, they anticipate Eyenovia's share price to reach $9.50 in the next year. This suggests a possible upside of 143.6% from the stock's current price. View Analyst Price Targets for Eyenovia.

What is the consensus analysts' recommendation for Eyenovia?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eyenovia in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Eyenovia.

Has Eyenovia been receiving favorable news coverage?

News coverage about EYEN stock has trended very negative recently, InfoTrie Sentiment reports. The research group ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Eyenovia earned a daily sentiment score of -4.0 on InfoTrie's scale. They also gave news stories about the company a news buzz of 6.0 out of 10, meaning that recent media coverage is somewhat likely to have an impact on the stock's share price in the next several days. View News Stories for Eyenovia.

Are investors shorting Eyenovia?

Eyenovia saw a increase in short interest in the month of February. As of February 14th, there was short interest totalling 313,100 shares, an increase of 21.6% from the January 30th total of 257,500 shares. Based on an average daily volume of 83,900 shares, the days-to-cover ratio is presently 3.7 days. Approximately 3.3% of the company's shares are short sold. View Eyenovia's Current Options Chain.

Who are some of Eyenovia's key competitors?

What other stocks do shareholders of Eyenovia own?

Who are Eyenovia's key executives?

Eyenovia's management team includes the folowing people:
  • Dr. Tsontcho Ianchulev M.P.H., M.D., MPH, CEO, Chief Medical Officer & Director (Age 46)
  • Ms. Jennifer Clasby, VP of Clinical Operations (Age 65)
  • Mr. Luke Clauson, VP of R&D (Age 40)
  • Mr. John P. Gandolfo, CFO & Sec. (Age 58)
  • Mr. Michael M. Rowe, VP of Marketing

When did Eyenovia IPO?

(EYEN) raised $30 million in an initial public offering (IPO) on Thursday, January 25th 2018. The company issued 2,700,000 shares at a price of $10.00-$12.00 per share. Ladenburg Thalmann and Roth Capital Partners​ acted as the underwriters for the IPO.

Who are Eyenovia's major shareholders?

Eyenovia's stock is owned by many different of retail and institutional investors. Top institutional shareholders include National Asset Management Inc. (0.07%) and Virtu Financial LLC (0.06%). Company insiders that own Eyenovia stock include Charles E Iv Mather, Curt H Labelle, John P Gandolfo, Michael M Rowe, Stuart M Grant and Tsontcho Ianchulev. View Institutional Ownership Trends for Eyenovia.

Which institutional investors are buying Eyenovia stock?

EYEN stock was purchased by a variety of institutional investors in the last quarter, including National Asset Management Inc. and Virtu Financial LLC. Company insiders that have bought Eyenovia stock in the last two years include Charles E Iv Mather, Curt H Labelle, John P Gandolfo, Michael M Rowe, Stuart M Grant and Tsontcho Ianchulev. View Insider Buying and Selling for Eyenovia.

How do I buy shares of Eyenovia?

Shares of EYEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Eyenovia's stock price today?

One share of EYEN stock can currently be purchased for approximately $3.90.

How big of a company is Eyenovia?

Eyenovia has a market capitalization of $64.12 million. The company earns $-17,250,000.00 in net income (profit) each year or ($1.82) on an earnings per share basis. View Additional Information About Eyenovia.

What is Eyenovia's official website?

The official website for Eyenovia is http://www.eyenoviabio.com/.

How can I contact Eyenovia?

Eyenovia's mailing address is 295 Madison Avenue Suite 2400, New York NY, 10017. The company can be reached via phone at 917-289-1117 or via email at [email protected]


MarketBeat Community Rating for Eyenovia (NASDAQ EYEN)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  129 (Vote Outperform)
Underperform Votes:  154 (Vote Underperform)
Total Votes:  283
MarketBeat's community ratings are surveys of what our community members think about Eyenovia and other stocks. Vote "Outperform" if you believe EYEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EYEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel